Presenting characteristics and progression of pediatric-onset morphea: Interim analysis of a prospective registry. Pediatr Dermatol 2023;40(4):606-609
Date
06/15/2023Pubmed ID
37317938DOI
10.1111/pde.15350Scopus ID
2-s2.0-85161830018 (requires institutional sign-in at Scopus site)Abstract
Morphea is a rare fibrosing disorder with a highly variable disease course, which can complicate management. Here, we present a prospective cohort study describing the current treatments used in the management of pediatric-onset morphea and assessing responses to systemic and topical therapies. Most patients demonstrated inactive disease by 1 year, regardless of treatment, though recurrences were common in our cohort overall (39%). Our results support the need for continuous monitoring of all children with morphea following the completion of treatment, including topical treatment, due to high rates of disease relapse.
Author List
Ng AT, Brandling-Bennett HA, Drolet BA, Siegel DH, Chiu YEAuthor
Yvonne E. Chiu MD Vice Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, TopicalChild
Humans
Prospective Studies
Rare Diseases
Scleroderma, Localized
